Leerink's Michael Cherny Calls July 23-24 PCAC Meeting a 'Modest Binary Event' for Hims & Hers (HIMS) with Real Upside Beginning FY27+ if Affirmative Vote Lands, Canaccord Genuity Reiterates Buy at $32 Price Target on Long-Term Peptide-Wellness-Longevity Thesis
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.